Characteristic | Before PSM | After PSM | ||||||
---|---|---|---|---|---|---|---|---|
All n = 227 (%) | Double-agent n = 91 (%) | Triple-agent n = 136 (%) | p-value | All n = 140 (%) | Double-agent n = 70 (%) | Triple-agent n = 70 (%) | p-value | |
Sex | ||||||||
 Male | 173 (76.2) | 68 (74.7) | 105 (77.2) | 0.786 | 107 (76.4) | 53 (75.7) | 54 (77.1) | 1 |
 Female | 54 (23.8) | 23 (25.3) | 31 (22.8) | 33 (23.6) | 17 (24.3) | 16 (22.9) | ||
Age | 59 [50,64] | 60 [50,64] | 59 [49,64] | 0.398 | 59[49, 64.25] | 59.5 [52.25, 64] | 56 [48.25, 66] | 0.347 |
  ≤ 60 years | 124 (93.8) | 48 (92.3) | 76 (94.9) | 0.684 | 78 (55.7) | 38 (54.3) | 40 (57.1) | 0.865 |
  > 60 years | 103 (6.2) | 43 (7.7) | 60 (5.1) | 62 (44.3) | 32 (45.7) | 30 (42.9) | ||
Diabetes mellitus | ||||||||
 Yes | 16 (7) | 5 (5.5) | 11 (8.1) | 0.485 | 12 (7.9) | 5 (6.7) | 7 (9.1) | 0.57 |
 No | 211 (93) | 86 (94.5) | 125 (91.9) | 140 (92.1) | 70 (93.3) | 70 (90.9) | ||
Location | ||||||||
 Upper | 87 (38.3) | 28 (30.8) | 59 (43.4) | 0.121 | 50 (35.7) | 25 (35.7) | 25 (35.7) | 1 |
 Middle | 49 (21.6) | 20 (22.0) | 29 (21.3) | 34 (24.3) | 17 (24.3) | 17 (24.3) | ||
 Lower | 91 (40.1) | 43 (47.3) | 48 (35.3) | 56 (40.0) | 28 (40.0) | 28 (40.0) | ||
Differentiation of adenocarcinoma | ||||||||
 Well | 7 (3.1) | 3 (3.3) | 4 (2.9) | 0.981 | – | – | – | 1 |
 Moderately | 66 (29.1) | 26 (28.6) | 40 (29.4) | 39 (27.9) | 20 (28.6) | 19 (27.1) | ||
 Poorly | 154 (67.8) | 62 (68.1) | 92 (67.6) | 101 (72.1) | 50 (71.4) | 51 (72.9) | ||
Clinical T stage | ||||||||
 T2 | 4 (1.8) | 2 (2.2) | 2 (1.5) | 0.512 | 2 (1.4) | 1 (1.4) | 1 (1.4) | 0.998 |
 T3 | 141 (62.1) | 61 (67.0) | 80 (58.8) | 87 (62.1) | 43 (61.4) | 44 (62.9) | ||
 T4a | 55 (24.2) | 20 (22.0) | 35 (25.7) | 35 (25.0) | 18 (25.7) | 17 (24.3) | ||
 T4b | 27 (11.9) | 8 (8.8) | 19 (14.0) | 16 (11.4) | 8 (11.4) | 8 (11.4) | ||
Clinical N stage | ||||||||
 N0 | 2 (0.9) | 2 (2.2) | 0 (0.0) | < 0.001 | – | – | – | 0.983 |
 N1 | 81 (35.7) | 48 (52.7) | 33 (24.3) | 61 (43.6) | 31 (44.3) | 30 (42.9) | ||
 N2 | 97 (42.7) | 29 (31.9) | 68 (50.0) | 55 (39.3) | 27 (38.6) | 28 (40.0) | ||
 N3 | 47 (20.7) | 12 (13.2) | 35 (25.7) | 24 (17.1) | 12 (17.1) | 12 (17.1) | ||
Clinical stage groupings | ||||||||
 IIA | 4 (1.8) | 2 (2.2) | 2 (1.5) | 0.22 | 2 (1.4) | 1 (1.4) | 1 (1.4) | 1 |
 IIB | 2 (0.9) | 2 (2.2) | 0 (0.0) | – | – | – | ||
 III | 194 (85.5) | 79 (86.8) | 115 (84.6) | 122 (87.1) | 61 (87.1) | 61 (87.1) | ||
 IVA | 27 (11.9) | 8 (8.8) | 19 (14.0) | 16 (11.4) | 8 (11.4) | 8 (11.4) | ||
Regimen | ||||||||
 FOLFOX6 | 8 (3.5) | 8 (8.8) | – |  | 4 (3.5) | 4 (5.7) | – |  |
 CAPOX | 12 (5.3) | 12 (13.2) | – |  | 7 (5.3) | 7 (10.0) | – |  |
 SOX | 71 (31.3) | 71 (78.0) | – | – | 59 (31.3) | 59 (84.3) | – | – |
 DCF | 5 (2.2) | – | 5 (3.7) |  | 4 (2.2) | – | 4 (5.7) |  |
 FLOT | 131 (57.7) | – | 131 (96.3) |  | 66 (57.7) | – | 66 (94.3) |  |
Cycles | 4.00[4.00,4.00] | 4.00[3.00,4.00] | 4.00[4.00,5.00] | < 0.001 | 4.00[4.00,4.00] | 4.00[3.00,4.00] | 4.00[4.00,5.00] | 0.006 |